Group net sales was EUR 31.7m in Q2 (Nordea est. EUR 30.
Redeye updates on Embracer after Q1-results which were overall close to our forecast, albeit with so...
Redeye states that BeammWave’s Q2 report aligned with expectations.
Q2 report due Friday, 23 August, at 07:00 CET '24e-'26e EBITA up 2-3%; 7% CAGR '23-'26e 12-9x EBITA ...
Investment management to be main earnings contributor in Q2 Continued weak market activity makes us ...
Pharma Equity Group (“PEG” or “the Company”) published its Q2 report for 2024 on the 16th of August ...
Redeye states BeammWave's Q2 report aligned with expectations.
We cut '25e-'26e EBITDA by 28-14% Aurdel restructuring to yield improvements in '25e '25e EV/EBIT of...
11% adj. EBITA miss but improvement already in Q3 '24e adj.
Lumi Gruppen continues to see high demand for its ONH courses, reporting a 20% y/y increase in autum...
Q2e: continued sales growth We expect sales of SEK 35m, up 9% y-o-y (+7% org.
Redeye maintains a positive view of Transtema following a Q2 beating our expectations.
Yesterday, August 14, Verrica presented its top line results from the phase II study of LTX-315 in b...
Ferronordic presented a muted set of Q2 numbers below our expectations, with organic sales declining...
Redeye updates on EG7 following its Q2-results which were in line with preliminary results.
Q2 numbers overall better than expected... Q2 numbers were better than we expected, with revenues of...
Relais reported Q2 adjusted EBITA of EUR 7.3m, 13% above LSEG Data & Analytics consensus.
Redeye strengthens its positive view of Transtema following a Q2 beating our expectations.
Redeye’s initial comments on the Q2 report from Waystream.
Redeye notes that Railcare is posting record level sales in Q2 while earnings were slightly below ou...
